Daniel Chao

Daniel Chao is an experienced executive in the biotechnology and healthcare sectors, currently serving as Operating Partner at Palo Santo since August 2023. Previously, Daniel held the role of Senior Advisor to the CEO at iBio, Inc., where responsibilities included leading the business integration of Rubryc into iBio while supporting leadership in deal making and fundraising strategies. As Chief Business Officer at Rubryc Therapeutics, Daniel managed deal assessment and negotiations for therapeutic antibody discovery. Daniel also served as CEO of Herophilus, navigating the company effectively through the pandemic to achieve a productive year. Prior significant roles include co-founding and leading Halo Neuroscience, where over $30 million was raised, and contributing to early-stage growth at NeuroPace, Inc. Daniel's educational background includes an MD and MS in Neuroscience from Stanford University School of Medicine and a BA in Biochemistry from the University of California, Berkeley.